-
Video
The Inflation Reduction Act- Explained by Incubate
12.15.2022
Incubate breaks down the Inflation Reduction Act, diving into implications and potential impacts on life science development. Keep up with...
-
Video
The Inflation Reduction Act: Implications for Biopharma Companies and Patients
09.23.2022
See our webinar, featuring DLA Piper, on the Inflation Reduction Act healthcare provisions.
-
Statement
Incubate Statement on Amendment 5284 of the Inflation Reduction Act
08.06.2022
Incubate issued the following statement in response to amendment 5284 of the Inflation Reduction Act:
-
Article
US Government Poised for Long-Awaited Powers on Drug Pricing
08.06.2022
Via Bloomberg: Drugmakers have long said R&D will suffer if prices regulated
-
Article
HEALTH CARE BRIEFING: Senate Drug Measures Cut Deficit, CBO Says
08.04.2022
Via Bloomberg Government: Senate Democrats’ tax, climate, and drug-pricing bill would cut down federal budget deficits by $102 billion over 10 years, the nonpartisan Congressional Budget Office said.
-
Article
Biotech Investors Sound the Alarm on Senate Drug Pricing Bill
08.03.2022
Via the Washington Times: A group of biotech investors and doctors are warning that the Senate’s drug-pricing proposal, aimed at lowering skyrocketing prices, would “strike a huge blow” to patient access and halt research on new treatments for Alzheimer’s disease, heart disease and cancer.
-
Article
Don’t Look Up? Congress Can’t Ignore Risk to Small Molecule Drugs in Pricing Bill, Investors Warn
08.03.2022
A budget-neutral fix that would extend the time before small molecule drugs are subject negotiations but increase the minimum discounts for the products is floated as the pricing legislation moves toward a Senate floor vote.
-
Video
Incubate Investor Panel on the Senate’s Inflation Reduction Act of 2022
08.03.2022
Members of Incubate's network, Peter Kolchinsky, PhD, Managing Partner at RA Capital Management; JF Formela, MD, Partner at Atlas Venture; Guarav Gupta, MD, MS - Founder and Managing Partner, Ascendant BioCapital; and Duane Schulthess, Managing Director of Vital Transformation, speak on the impacts of the Inflation Reduction Act on the early-stage life science industry.
-
Statement
Incubate Letter on Reconciliation Drug Pricing Provisions
07.15.2022
Read Incubate's letter to the US Senate on their recent drug price provisions in the Reconciliation package
-
Statement
Incubate Statement on Federal Drug Price Provisions
07.06.2022
See Incubate's statement in response to the recent Reconciliation bill text on drug price controls.
-
Statement
Incubate Statement on WTO Decision to Suspend Global IP Rights
06.30.2022
The Incubate Coalition issued the following statement preceding the WTO TRIPS Council meeting (July 6-7) and following the World Trade Organization’s decision at its 12th Ministerial Conference in Geneva, Switzerland to waive intellectual property (IP) protections for Covid-19 vaccines.
-
Article
LTE: Patents protect people’s access to life-saving medicine
06.05.2022
See Incubate's letter to the editor about why patents are necessary in protecting patient access.
Resources
